BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38686708)

  • 1. Dose Optimization Informed by PBPK Modeling: State-of-the Art and Future.
    Rowland Yeo K; Gil Bergland E; Chen Y
    Clin Pharmacol Ther; 2024 Apr; ():. PubMed ID: 38686708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.
    Tsakalozou E; Mohamed MF; Polak S; Heimbach T
    AAPS J; 2023 Oct; 25(6):96. PubMed ID: 37783902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
    Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Isoherranen N
    Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38326033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective.
    Lin W; Chen Y; Unadkat JD; Zhang X; Wu D; Heimbach T
    Pharm Res; 2022 Aug; 39(8):1701-1731. PubMed ID: 35552967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review: Role of Model-Informed Drug Development Approaches in the Lifecycle of Drug Development and Regulatory Decision-Making.
    Madabushi R; Seo P; Zhao L; Tegenge M; Zhu H
    Pharm Res; 2022 Aug; 39(8):1669-1680. PubMed ID: 35552984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of Model-Informed Drug Development in Dose Selection and Optimization for siRNA Therapies.
    Yuan Y; Li L; Earp J; Ma L; Bhattaram VA; Sharma V; Tong A; Wang Y; Liu J; Zhu H
    J Clin Pharmacol; 2024 Mar; ():. PubMed ID: 38426370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
    Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
    AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations.
    Taskar KS; Pilla Reddy V; Burt H; Posada MM; Varma M; Zheng M; Ullah M; Emami Riedmaier A; Umehara KI; Snoeys J; Nakakariya M; Chu X; Beneton M; Chen Y; Huth F; Narayanan R; Mukherjee D; Dixit V; Sugiyama Y; Neuhoff S
    Clin Pharmacol Ther; 2020 May; 107(5):1082-1115. PubMed ID: 31628859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Model-Informed Drug Development in Pediatric Drug Development, Regulatory Evaluation, and Labeling.
    Bi Y; Liu J; Li L; Yu J; Bhattaram A; Bewernitz M; Li RJ; Liu C; Earp J; Ma L; Zhuang L; Yang Y; Zhang X; Zhu H; Wang Y
    J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S104-S111. PubMed ID: 31502691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
    Samineni D; Ding H; Ma F; Shi R; Lu D; Miles D; Mao J; Li C; Jin J; Wright M; Girish S; Chen Y
    J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S120-S131. PubMed ID: 33205435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological-based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20-years; in-depth analysis of applications, organizations, and platforms.
    El-Khateeb E; Burkhill S; Murby S; Amirat H; Rostami-Hodjegan A; Ahmad A
    Biopharm Drug Dispos; 2021 Apr; 42(4):107-117. PubMed ID: 33325034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.
    Wagner C; Zhao P; Pan Y; Hsu V; Grillo J; Huang SM; Sinha V
    CPT Pharmacometrics Syst Pharmacol; 2015 Apr; 4(4):226-30. PubMed ID: 26225246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of
    Loisios-Konstantinidis I; Dressman J
    Mol Pharm; 2021 Jan; 18(1):1-17. PubMed ID: 33320002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-Depth Analysis of Physiologically Based Pharmacokinetic (PBPK) Modeling Utilization in Different Application Fields Using Text Mining Tools.
    Krstevska A; Đuriš J; Ibrić S; Cvijić S
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678737
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Foti RS
    Drug Metab Dispos; 2024 Jan; ():. PubMed ID: 38290748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory utility of physiologically-based pharmacokinetic modeling to support alternative bioequivalence approaches and risk assessment: A workshop summary report.
    Wu F; Mousa Y; Raines K; Bode C; Tsang YC; Cristofoletti R; Zhang H; Heimbach T; Fang L; Kesisoglou F; Mitra A; Polli J; Kim MJ; Fan J; Zolnik BS; Sun D; Zhang Y; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2023 May; 12(5):585-597. PubMed ID: 36530026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physiologically-based pharmacokinetic models for children: Starting to reach maturation?
    Verscheijden LFM; Koenderink JB; Johnson TN; de Wildt SN; Russel FGM
    Pharmacol Ther; 2020 Jul; 211():107541. PubMed ID: 32246949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
    Saeheng T; Na-Bangchang K; Karbwang J
    Eur J Clin Pharmacol; 2018 Nov; 74(11):1365-1376. PubMed ID: 29978293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.